Comparative Biosciences

What Comparative Biosciences does

Comparative Biosciences, Inc. (CBI) is a preclinical contract research organization (CRO) founded in 1996 and headquartered in Sunnyvale, California, providing GLP-compliant toxicology, pharmacokinetics, and efficacy studies to pharmaceutical, biotechnology, medical device, academic, and federal research clients. The company operates from a 20,000-square-foot AAALAC-accredited vivarium equipped for small and large animal studies, with in-house histopathology, immunohistochemistry, in situ hybridization, tissue cross-reactivity, and digital image analysis, complemented by advanced imaging platforms including a Bioptigen Envisu R2200 spectral-domain OCT system, digital radiography, ultrasound, MRI, and IVIS. CBI maintains validated specialty models across dermatology, ophthalmology, oncology, cardiovascular, CNS, inflammation, otic/auditory, infectious disease, and stem cell programs, with proprietary methodology such as Phase Contrast Analysis for hyperoxygenation alveolar assessment and a structured three-phase Tissue Cross-Reactivity service aligned to FDA/EMA expectations.

CBI's business model is fee-for-service professional services revenue under project-based, custom-designed study contracts priced via quote; go-to-market is direct enterprise field sales augmented by content (white papers, bulletins, publications), email newsletter, and physical presence at industry conferences (ARVO, SOT, ACT). Service breadth is horizontal across therapeutic areas, with vertical depth in ocular, dermal, otic, oncology, and biocompatibility niches where validated models and specialized equipment differentiate the offering. The company holds AAALAC, FDA, USDA, OLAW, GLP, ISO-10993, and ISO-9394 credentials, and its board-certified pathologists have authored over 100 peer-reviewed publications, supporting scientific credibility with regulatory-grade sponsors.

Since August 2020, CBI has operated as a wholly-owned subsidiary within Genesis Biotechnology Group, functioning as the GLP toxicology and safety pharmacology arm of the Genesis Drug Discovery & Development (GD3) division. Through GD3, CBI is embedded in a broader CRO platform that has expanded via acquisition (STATKING 2021, BioBlocks 2021, Genesis Axis/Organochem 2023, JSS Medical Research 2023) into clinical trial services and chemistry, providing cross-sell and integrated program pathways from target discovery through Phase I–III trial management, while CBI retains its operational identity and specialty focus.

Name

Comparative Biosciences

Legal name

Comparative Biosciences, Inc.

Website

https://compbio.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Comparative Biosciences is a Sunnyvale-based preclinical CRO providing GLP-compliant toxicology, pharmacokinetics, histopathology, and efficacy studies across dermatology, ophthalmology, oncology, cardiovascular, CNS, and otic models for pharmaceutical, biotech, academic, federal, and medical device sponsors.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Preclinical CRO services
• GLP toxicology studies
• Pharmacokinetics research
• Histopathology services
• Animal model research

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research Services (Preclinical CRO): CBI generates revenue through fee-for-service preclinical contract research agreements. Services include toxicology studies (GLP and non-GLP), pharmacokinetics, pharmacodynamics, biodistribution, histopathology, immunohistochemistry, and efficacy studies across multiple therapeutic areas. Studies are custom-designed per sponsor requirements and priced on a project-by-project basis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Comparative Biosciences is a preclinical Contract Research Organization (CRO) that designs and executes GLP-compliant toxicology, pharmacokinetics, pharmacodynamics, biodistribution, and efficacy studies in validated animal models. It delivers these studies together with in-house histopathology, immunohistochemistry, tissue cross-reactivity, and specialized imaging (including OCT), supporting IND, 510(k), NDA, and BLA regulatory submissions for pharmaceutical, biotechnology, medical device, academic, and federal clients.

Product overview

Comparative Biosciences, Inc. (CBI) is a preclinical Contract Research Organization (CRO) offering an integrated suite of toxicology, pharmacokinetics, and histopathology services. The core platform consists of GLP-compliant preclinical studies supporting drug discovery from early assessment through regulatory submission. Key service modules include: Toxicology Services (discovery, investigative, regulatory, ocular, dermal, otic, and stem cell toxicology); Pharmacokinetics Services (preclinical PK, TK, bioavailability, bioequivalence, ADME); Histopathology Services (histology, special stains, immunohistochemistry, in situ hybridization, tissue cross-reactivity, digital analysis); and specialized therapeutic area services spanning dermatology, ophthalmology, oncology, cardiovascular, inflammation, CNS, veterinary pharmacology, cannabis pharmacology, and biocompatibility/device testing. Additional technology offerings include Optical Coherence Tomography (OCT) imaging. The company operates as a member of Genesis Drug Discovery & Development (GD3) within Genesis Global Group, is AAALAC accredited, and FDA registered.

Differentiator

Problem solved

Functional benefit

Products and services

• Toxicology Services Preclinical toxicology studies spanning discovery, investigative, and regulatory toxicology; systemic and localized toxicity; acute and chronic assessments; and specialized ocular, dermal, otic, and stem cell toxicology studies supporting IND-enabling programs for pharmaceutical and biotech sponsors.
• Pharmacokinetics Services Preclinical pharmacokinetic, toxicokinetic, bioavailability, bioequivalence, and ADME studies conducted in normal and disease-state animal models, designed to support regulatory submissions.
• Histopathology Services Contract histology, histopathology, immunohistochemistry, special stains, in situ hybridization, tissue cross-reactivity, histomorphometry, and digital slide analysis services for preclinical studies, medical devices, and plastics, with board-certified veterinary pathologist oversight.
• Dermatology Preclinical Services Dermal preclinical services including wound healing models, dermal burn modeling, dermatologic inflammation, delayed-type hypersensitivity studies, dermal pharmacokinetics, and dermal toxicology for pharmaceutical and biotech sponsors.
• Ophthalmology Preclinical Services Ocular pharmacology and efficacy models, ocular pharmacokinetics, ocular toxicology, and Optical Coherence Tomography (OCT) imaging services for ophthalmic drug development and device assessment.
• Oncology Preclinical Services Preclinical oncology pharmacology models, validated tumor cell line xenograft studies (subcutaneous, orthotopic, intravenous), and GLP/non-GLP IND-enabling toxicology and pharmacokinetic studies for cancer therapeutics and immunotherapies.
• Cardiovascular Preclinical Services Cardiovascular efficacy models, hyperoxia injury models, atherosclerosis studies, and therapeutic hyperoxia injury assessments for cardiovascular drug development.
• Inflammation Preclinical Services Preclinical inflammation studies including immune-mediated disease models, diabetic and metabolic models, dermatologic inflammation, and arthritis models for anti-inflammatory drug development.
• Specialized CNS Pharmacology Customized surgical CNS pharmacology and efficacy models, GLP and non-GLP CNS toxicity studies, pharmacokinetic assessments in CNS tissues, and specialized dosing studies for neurological drug development.
• Veterinary Pharmacology Toxicology, pharmacokinetic, and pharmacology studies for the veterinary and animal health industry designed to support USDA and FDA regulatory submissions for animal health products.
• Cannabis Pharmacology Purity, efficacy, and safety assessment services for cannabis products, including in vitro assays, rodent toxicity studies, and bioanalytical assays to support cannabis product development.
• Biocompatibility and Medical Device Safety Services Safety evaluation and biocompatibility testing for medical devices compliant with ISO-10993, ISO-9394, and US Pharmacopeial standards to support 510(k), NDA, and international device submissions.
• Stem Cell Toxicology and Research Stem cell toxicology research, efficacy studies, pharmacokinetics, biodistribution, combination device studies, and FDA-compliant regulatory packages for cell-based therapeutics.
• Tissue Cross-Reactivity (TCR) Studies Structured three-phase Tissue Cross-Reactivity program supporting development of monoclonal antibodies and biologics, including a 37-tissue preliminary screen and full GLP study compliant with FDA and EMA regulatory recommendations.
• Ototoxicity and Auditory Studies Preclinical IND-enabling otic and auditory toxicology, efficacy, and PK/PD studies, including auditory brainstem response (ABR) assessments, delivered in collaboration with Turner Scientific.

Quantifiable outcome

• Rapid study scheduling achievable within 1-2 weeks from scheduling to specimen delivery, supporting tight sponsor timelines
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered minor, notable and core.

• Genesis Drug Discovery & Development (GD3) / JSS Medical ResearchminorOthers · 1 May 2023In May 2023, Genesis Drug Discovery & Development (a member of Genesis Global Group, CBI's parent organization) acquired JSS Medical Research to expand its clinical services portfolio. CBI, as a member of GD3, benefits from this group-level expansion of services.
• Genesis Axis / OrganochemminorOthers · 1 January 2023In January 2023, Genesis Axis acquired Organochem to grow the preclinical chemistry services portfolio. CBI, as part of the Genesis Global Group ecosystem, benefits from expanded chemistry capabilities at the group level.
• Genesis Drug Discovery & Development (GD3) / BioBlocksminorOthers · 1 October 2021In October 2021, Genesis Biotechnology Group acquired BioBlocks to grow the preclinical chemistry services portfolio of Genesis Drug Discovery & Development (GD3), CBI's parent division.
• Genesis Drug Discovery & Development (GD3) / STATKING Clinical ServicesminorOthers · 1 January 2021Genesis Drug Discovery and Development expanded its presence in the clinical space by acquiring STATKING Clinical Services in January 2021, extending the group's capabilities from preclinical into clinical trial services.
• Yale UniversitynotableStrategic or Co-development Partner · 1 December 2020Genesis Biotechnology Group announced a second year of CRO relationship with Yale University in December 2020, indicating an ongoing partnership for preclinical research services. CBI, as a member of Genesis Global Group, participates in these relationships.
• Genesis Biotechnology Group / Genesis Drug Discovery & Development (GD3)coreOthers · 1 August 2020Genesis Biotechnology Group (parent company) acquired CBI in August 2020 to add GLP Toxicology and Safety Pharmacology to its portfolio of Preclinical Services under the Genesis Drug Discovery & Development (GD3) division. CBI operates as a member of GD3, a fully integrated CRO providing services from target discovery through IND filing and Phase I-III clinical trials management.
• Turner ScientificnotableStrategic or Co-development Partner · 1 November 2017Turner Scientific, led by Dr. Jeremy Turner (a world-renowned expert in preclinical ototoxicology), collaborates with CBI on otic toxicology studies and auditory brainstem response (ABR) assessments. CBI sponsored a Specialty Seminar at ACT 2017 entitled 'Preclinical Screening for the New FDA Guidelines' presented by Dr. Turner. This collaboration positions CBI as one of few CROs providing specialty preclinical IND-enabling otic and auditory toxicology, efficacy, and PK/PD studies.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Inotiv: Inotiv is a preclinical CRO providing toxicology, safety assessment, PK, and research models across pharma and medical device clients. Its service scope, GLP toxicology focus, and mid-sized CRO positioning make it a direct comparable to CBI.
• Calvert Laboratories: Calvert Laboratories is a preclinical CRO providing general toxicology, safety pharmacology, and PK services. Its mid-sized toxicology-focused service profile directly mirrors CBI's core offering.
• Toxikon: Toxikon is a preclinical CRO specializing in GLP toxicology, pharmacokinetics, and medical device biocompatibility testing (ISO 10993). It directly competes with CBI on regulatory toxicology and device biocompatibility services.
• NAMSA: NAMSA is a medical device-focused preclinical CRO offering ISO 10993 biocompatibility, GLP toxicology, and regulatory consulting. It directly competes with CBI's medical device biocompatibility and specialized toxicology offerings.
• Sinclair Research Center: Sinclair Research Center is a preclinical CRO offering toxicology, pharmacokinetics, and efficacy models to pharma and medical device sponsors. Its specialty toxicology and small-animal study focus make it a closely comparable peer to CBI.
• ITR Laboratories Canada: ITR Laboratories is a preclinical CRO providing general toxicology, safety pharmacology, and bioanalysis for pharmaceutical and biotech clients. Its scope and CRO-only positioning align closely with CBI's services.

Broad incumbents

• Labcorp Drug Development (formerly Covance): Labcorp Drug Development is one of the largest global CROs offering preclinical toxicology, PK, and central lab services alongside clinical and bioanalytical. It competes with CBI on GLP toxicology but at much larger scale and broader scope.
• WuXi AppTec: WuXi AppTec is a global CRO/CDMO providing preclinical toxicology, DMPK, and laboratory testing services to pharma and biotech. Its large-scale preclinical operations and integrated discovery-to-manufacturing platform overlap directly with CBI's GLP toxicology and PK services.
• Charles River Laboratories: Charles River Laboratories is the global leader in preclinical contract research, offering GLP toxicology, safety pharmacology, PK, and discovery services to pharma and biotech. It is the dominant scaled incumbent competing with CBI for IND-enabling study work.
• Eurofins Scientific: Eurofins Scientific is a global life sciences testing group offering central laboratory, bioanalytical, and preclinical research services. It is a broad incumbent competing with CBI in pharma testing and preclinical research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/comparative-biosciences

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Comparative Biosciences